Core Viewpoint - MicroPort Robotics (02252) has successfully completed the world's first "large model autonomous surgery" in vivo animal experiments using its self-developed "Neuron MicroGenius" multimodal autonomous surgical model, marking a significant milestone in surgical robotics [1] Group 1: Company Achievements - The company’s stock rose over 7% in early trading, currently up 5.7% at HKD 26.7, with a trading volume of HKD 115 million [1] - The successful animal experiment is unprecedented in existing literature and medical practice, showcasing the capability of the multimodal autonomous surgical model to perform key surgical steps autonomously in a living organism [1] Group 2: Order Statistics - The company reported that the cumulative order volume for its core products in endoscopy, orthopedics, and vascular intervention has surpassed 230 units [1] - The core product, the TiMai endoscopic surgical robot, has achieved over 160 commercial orders globally, with nearly 120 new orders received this year [1] - According to public statistics, the TiMai robot is projected to rank among the top two in global order volume by 2025 [1]